# Kunio Okamoto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kunio-okamoto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,297 |
| Field | Chemical Reaction Mechanisms |
| h-index | 23 |
| i10-index | 73 |
| Last Known Institution | Kagawa Prefectural Central Hospital |
| OpenAlex ID | https://openalex.org/A5047822717 |
| ORCID iD | 0000-0001-7959-7089 |
| Works | 282 |

## Researcher papers

- [Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection](https://scholariq.org/papers/risk-factors-for-cisplatin-induced-nephrotoxicity-and-potential-of-magnesium/)
- [MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations](https://scholariq.org/papers/met-tyrosine-kinase-inhibitor-crizotinib-pf-02341066-shows-differential/)
- [Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for <i>EGFR</i> Mutations](https://scholariq.org/papers/role-of-survivin-in-egfr-inhibitor-induced-apoptosis-in-non-small-cell-lung/)
- [The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells](https://scholariq.org/papers/the-anti-her3-antibody-patritumab-abrogates-cetuximab-resistance-mediated-by/)
- [Overcoming Erlotinib Resistance in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin](https://scholariq.org/papers/overcoming-erlotinib-resistance-in-i-egfr-i-mutation-positive-non-small-cell/)
- [Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition](https://scholariq.org/papers/identification-of-c-src-as-a-potential-therapeutic-target-for-gastric-cancer-and/)
- [Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors](https://scholariq.org/papers/phase-i-study-of-amatuximab-a-novel-monoclonal-antibody-to-mesothelin-in/)
- [1,2:3,4:5,6-Tris(bicyclo\[2.2.2\]octeno)tropylium ion: an all-hydrocarbon carbocation with extraordinary stability](https://scholariq.org/papers/1-2-3-4-5-6-tris-bicyclo-2-2-2-octeno-tropylium-ion-an-all-hydrocarbon/)
- [Isolation and properties of hydrocarbon salts](https://scholariq.org/papers/isolation-and-properties-of-hydrocarbon-salts/)
- [High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin](https://scholariq.org/papers/high-dose-dexamethasone-plus-antihistamine-prevents-colorectal-cancer-patients/)
- [Re-biopsy of twelve non small cell lung cancer (NSCLC) cases](https://scholariq.org/papers/re-biopsy-of-twelve-non-small-cell-lung-cancer-nsclc-cases/)

## Researcher topics

- [Inorganic and Organometallic Chemistry](https://scholariq.org/topics/inorganic-and-organometallic-chemistry/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Analytical Chemistry and Chromatography](https://scholariq.org/topics/analytical-chemistry-and-chromatography/)

## Researcher university

- [Kagawa Prefectural Central Hospital](https://scholariq.org/institutions/kagawa-prefectural-central-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.